Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator-initiated and Open-labeled Clinical Trial for Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

NCT04657315 is registered in ClinicalTrials.gov with CHA University as lead sponsor.

NCT NCT04657315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04657315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator-initiated and Open-labeled Clinical Trial for Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
Lead sponsor
CHA University
Phase
Phase 1/2
Overall status
Completed
Start date
June 24, 2020
Completion date
December 22, 2022
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult gliosarcoma, glioblastoma, neoplasms, brain, neoplasms, germ cell and embryonal, recurrent glioblastoma